Uvax Bio appoints Kevin O’Neill as interim chief executive

4 February 2025

Uvax Bio, a privately held vaccine developer founded in 2018 as a spin-off from Scripps Research, has appointed chief business officer Kevin O’Neill as interim chief executive.

Mr O’Neill, who joined Uvax Bio in 2022 and will succeed co-founder Ji Li, will take over the reins while the board searches for a permanent chief executive.

Formerly senior VP of corporate strategy at Uvax, he has also held leadership roles at Pfizer Vaccines, where he led the global commercialization effort for Prevnar 13 (pneumococcal 13-valent conjugate vaccine), and at LSBS, a vaccine development and commercialization consulting firm.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK